Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism
Completed
- Conditions
- Venous Thromboembolism
- Registration Number
- NCT04477564
- Lead Sponsor
- Centre Hospitalier Universitaire de Nīmes
- Brief Summary
The aim of the study is to investigate the existence of clonal hematopoiesis of indeterminate potential (CHIP) in patients with a history of venous thromboembolism.
The study investigators make the assumption that these patients present mutations involved in CHIP occurrence.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- Men and women over 50 years old who have consulted at the Hematology laboratory of the Nîmes University Hospital for the occurrence or history of venous thromboembolism
- Patient who has accepted that their DNA was kept and used in the context of research on venous thromboembolism (biobank (registration number DC-2008-290 and authorization number AC-2008-107))
Exclusion Criteria
- Patients less than 50 years old
- Patient who has refused that their DNA was kept and used in the context of research on venous thromboembolism
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method DNMT3A mutations screening For sequencing analysis: 2 months Next generation sequencing
- Secondary Outcome Measures
Name Time Method TET2, ASXL1, TP53, JAK2, SF3B1, SRSF2, GNB1, CBL, BCOR, SH2B3, PPM1D mutations screening For sequencing analysis: 2 months Next generation sequencing
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link CHIP mutations to venous thromboembolism pathogenesis?
Are CHIP-related biomarkers associated with increased VTE recurrence risk in observational studies?
How does clonal hematopoiesis affect standard anticoagulant therapy outcomes in VTE patients?
What adverse events are reported in CHIP screening studies for thrombotic disorders?
What role do DNMT3A, TET2, or ASXL1 mutations play in VTE patient risk stratification?
Trial Locations
- Locations (1)
CHU de Nimes
🇫🇷Nîmes, France
CHU de Nimes🇫🇷Nîmes, France